Delay and attrition before treatment initiation among MDR-TB patients in five districts of Gujarat, India

被引:16
|
作者
Shewade, H. D. [1 ,2 ]
Shringarpure, K. S. [3 ]
Parmar, M. [4 ]
Patel, N. [3 ]
Kuriya, S. [3 ]
Shihora, S. [3 ]
Ninama, N. [3 ]
Gosai, N. [3 ]
Khokhariya, R. [3 ]
Popat, C. [3 ]
Thanki, H. [4 ]
Modi, B. [5 ]
Dave, P. [6 ]
Baxi, R. K. [3 ]
Kumar, A. M. V. [1 ,2 ]
机构
[1] Int Union TB & Lung Dis, South East Asia Off, New Delhi 110016, India
[2] The Union, Paris, France
[3] Med Coll, Dept Prevent & Social Med, Vadodara, India
[4] World Hlth Org Country Off India, New Delhi, India
[5] Gujarat Med Educ & Res Soc, Med Coll & Hosp, Dept Community Med, Gandhinagar, India
[6] Govt Gujarat, Dept Hlth & Family Welf, Gandhinagar, India
来源
PUBLIC HEALTH ACTION | 2018年 / 8卷 / 02期
关键词
multidrug-resistant tuberculosis; prevention and control; operational research; India; initial loss to follow-up;
D O I
10.5588/pha.18.0003
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Setting: Gujarat, a state in west India. Background: Although treatment initiation has been improving among patients diagnosed with multidrug-resistant tuberculosis (MDR-TB) in programme settings, it has still not reached 100%. Objectives: To determine pre-treatment attrition (not initiated on treatment within 6 months of diagnosis), delay in treatment initiation (>7 days from diagnosis) and associated factors among MDR-TB patients diagnosed in 2014 in five selected districts served by two genotypic drug susceptibility testing (DST) facilities and a drug-resistant TB centre in Gujarat. Design: This was a retrospective cohort study involving record review. Results: Among 257 MDR-TB patients, pre-treatment attrition was seen in 20 (8%, 95% CI 5-12). Patients with 'follow-up sputum-positive' as their DST criterion and sputum smear microscopy status 'unknown' at the time of referral for DST were less likely to be initiated on treatment. The median delay to treatment initiation was 8 days (interquartile range 6-13). Patients referred for DST from medical colleges were more likely to face delays in treatment initiation. Conclusion: The Gujarat TB programme is performing well in initiating laboratory-confirmed MDR-TB patients on treatment. However, there is further scope for reducing delay.
引用
收藏
页码:59 / 65
页数:7
相关论文
共 50 条
  • [21] MDR-TB treatment needs in patients previously treated for TB in Cotonou, Benin
    Ade, S.
    Trebucq, A.
    Harries, A. D.
    Affolabi, D.
    Ade, G.
    Agodokpessi, G.
    Wachinou, P.
    Anagonou, S.
    Gninafon, M.
    PUBLIC HEALTH ACTION, 2013, 3 (02): : 160 - 165
  • [22] Clinical management improves the treatment outcome of MDR-TB patients
    Chen, Ling
    Liu, Quanxian
    Li, Yuqin
    Zhang, Jianyong
    Zhang, Hong
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [23] Outcome of Standardized Treatment of MDR-TB Among Young Females at Drug Resistance TB (DR-TB) Center, Patiala, India
    Bhatnager, Arjun
    Kumari, Sudesh
    Poduvattil, Prasanth
    Abraham, Jebin
    Bharti, Anu
    CHEST, 2017, 152 (04) : 195A - 195A
  • [24] Drug resistance and associated genetic mutations among patients with suspected MDR-TB in Uttar Pradesh, India
    Jain, A.
    Singh, P. K.
    Chooramani, G.
    Dixit, P.
    Malhotra, H. S.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2016, 20 (07) : 870 - 875
  • [25] High pre-diagnosis attrition among patients with presumptive MDR-TB: an operational research from Bhopal district, India (vol 17, 249, 2017)
    Shewade, Hemant Deepak
    Kokane, Arun M.
    Singh, Akash Ranjan
    Verma, Manoj
    Parmar, Malik
    Chauhan, Ashish
    Chahar, Sanjay Singh
    Tiwari, Manoj
    Khan, Sheeba Naz
    Gupta, Vivek
    Tripathy, Jaya Prasad
    Nagar, Mukesh
    Singh, Sanjai Kumar
    Mehra, Pradeep Kumar
    Kumar, Ajay M. V.
    BMC HEALTH SERVICES RESEARCH, 2017, 17
  • [26] Prevalence and Factors Associated with Multidrug-Resistant Tuberculosis (MDR-TB) among Presumptive MDR-TB Patients in Tigray Region, Northern Ethiopia
    Mehari, Kibriti
    Asmelash, Tsehaye
    Hailekiros, Haftamu
    Wubayehu, Tewolde
    Godefay, Hagos
    Araya, Tadele
    Saravanan, Muthupandian
    CANADIAN JOURNAL OF INFECTIOUS DISEASES & MEDICAL MICROBIOLOGY, 2019, 2019
  • [27] Management and treatment outcomes of patients enrolled in MDR-TB treatment in Viet Nam
    Phuong, N. T. M.
    Nhung, N. V.
    Hoa, N. B.
    Thuy, H. T.
    Takarinda, K. C.
    Tayler-Smith, K.
    Harries, A. D.
    PUBLIC HEALTH ACTION, 2016, 6 (01): : 25 - 31
  • [28] Impact of social support programme on MDR-TB patients' treatment outcomes
    Testov, Vadim
    Sterlikov, Sergey
    Vasilyeva, Irina
    Erokhin, Vladislav
    Kasayeva, Teresa
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [29] Adverse Events among HIV/MDR-TB Co-Infected Patients Receiving Antiretroviral and Second Line Anti-TB Treatment in Mumbai, India
    Isaakidis, Petros
    Varghese, Bhanumati
    Mansoor, Homa
    Cox, Helen S.
    Ladomirska, Joanna
    Saranchuk, Peter
    Da Silva, Esdras
    Khan, Samsuddin
    Paryani, Roma
    Udwadia, Zarir
    Migliori, Giovanni Battista
    Sotgiu, Giovanni
    Reid, Tony
    PLOS ONE, 2012, 7 (07):
  • [30] Current and developing therapies for the treatment of multi drug resistant tuberculosis (MDR-TB) in India
    Muniyandi, Malaisamy
    Ramachandran, Rajeswari
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (13) : 1301 - 1309